Exchange: OTC·Updated 11:18 AM EDT

PTPDF Pentixapharm Holding AG

$2.31
$0.00
(0.00%)
Today
Vol16,500.00

About PTPDF

Pentixapharm Holding AG engages in the development of radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company was founded in 2024 and is headquartered in Berlin, Germany.
50

Neutral Sentiment

How do you feel about PTPDF?

bierre_price
$PTPDF From a NuWays research: „Pentixapharm sits at the intersection of a high-prevalence indication and one of the fastest-growing fields of medicine: radiopharma. Following the recent capital increase, the company is now well positioned to enter Phase 3 with its lead diagnostic agent PentixaFor from a position of financial strength, with several catalysts ahead. Financing secured. PTP has placed the full c. 11.0m new shares at € 1.85, raising net proceeds of c. € 19.7m. Anchor shareholder Eckert Wagniskapital (c. 36%) exercised the rights issue in full and the residual tranche was materially oversubscribed. Pro forma cash of c. € 25m (eNuW), vs. c. € 5m previously, extends the runway from Q1 2027 into early 2028 and covers the initial execution phase of PANDA, the Phase 3 study for PentixaFor (eNuW). As a result, the company can comfortably enter this next stage, with two key catalysts ahead:

Advertisement|Remove ads.